60 related articles for article (PubMed ID: 20665886)
1. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
Kelly CM; Krishnamurthy S; Bianchini G; Litton JK; Gonzalez-Angulo AM; Hortobagyi GN; Pusztai L
Cancer; 2010 Nov; 116(22):5161-7. PubMed ID: 20665886
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
3. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Cuzick J; Dowsett M; Pineda S; Wale C; Salter J; Quinn E; Zabaglo L; Mallon E; Green AR; Ellis IO; Howell A; Buzdar AU; Forbes JF
J Clin Oncol; 2011 Nov; 29(32):4273-8. PubMed ID: 21990413
[TBL] [Abstract][Full Text] [Related]
5. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype.
Makhlouf S; Atallah NM; Polotto S; Lee AHS; Green AR; Rakha EA
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791971
[TBL] [Abstract][Full Text] [Related]
7. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights.
Batra H; Mouabbi JA; Ding Q; Sahin AA; Raso MG
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001750
[TBL] [Abstract][Full Text] [Related]
8. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.
Licata L; Viale G; Giuliano M; Curigliano G; Chavez-MacGregor M; Foldi J; Oke O; Collins J; Del Mastro L; Puglisi F; Montemurro F; Vernieri C; Gerratana L; Giordano S; Rognone A; Sica L; Gentilini OD; Cascinu S; Pusztai L; Giordano A; Criscitiello C; Bianchini G
NPJ Breast Cancer; 2023 Jun; 9(1):51. PubMed ID: 37291235
[TBL] [Abstract][Full Text] [Related]
9. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
Mouabbi JA; Hassan A; Lim B; Hortobagyi GN; Tripathy D; Layman RM
Breast Cancer Res Treat; 2022 Jun; 193(2):253-264. PubMed ID: 35347549
[TBL] [Abstract][Full Text] [Related]
10. Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review.
Glaab E; Rauschenberger A; Banzi R; Gerardi C; Garcia P; Demotes J
BMJ Open; 2021 Dec; 11(12):e053674. PubMed ID: 34873011
[TBL] [Abstract][Full Text] [Related]
11. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer.
Maranta AF; Broder S; Fritzsche C; Knauer M; Thürlimann B; Jochum W; Ruhstaller T
Breast; 2020 Jun; 51():120-126. PubMed ID: 32302928
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
[TBL] [Abstract][Full Text] [Related]
13. Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.
Wang W; Chen X; Lin L; Fei X; Garfield DH; Hong J; Gao W; Zhu S; Wu J; Huang O; He J; Li Y; Zhu L; Chen W; Shen K
J Cancer; 2018; 9(18):3216-3224. PubMed ID: 30271480
[TBL] [Abstract][Full Text] [Related]
14. Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
Tadros AB; Wen HY; Morrow M
Ann Surg Oncol; 2018 Oct; 25(11):3158-3164. PubMed ID: 30094484
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of gene-expression signatures in early stage breast cancer.
Kwa M; Makris A; Esteva FJ
Nat Rev Clin Oncol; 2017 Oct; 14(10):595-610. PubMed ID: 28561071
[TBL] [Abstract][Full Text] [Related]
16. Strategies for power calculations in predictive biomarker studies in survival data.
Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Pourteimoor V; Mohammadi-Yeganeh S; Paryan M
Tumour Biol; 2016 Nov; 37(11):14479-14499. PubMed ID: 27651157
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and the recurrence score--results as expected?
Pusztai L
Nat Rev Clin Oncol; 2015 Dec; 12(12):690-2. PubMed ID: 26552957
[No Abstract] [Full Text] [Related]
19. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Potosky AL; O'Neill SC; Isaacs C; Tsai HT; Chao C; Liu C; Ekezue BF; Selvam N; Kessler LG; Zhou Y; Schwartz MD
Cancer; 2015 Nov; 121(22):4062-70. PubMed ID: 26291519
[TBL] [Abstract][Full Text] [Related]
20. Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
Conlon N; Ross DS; Howard J; Catalano JP; Dickler MN; Tan LK
Breast J; 2015; 21(5):514-9. PubMed ID: 26271749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
